Omicron breakthrough infections in vaccinated or previously infected hamsters.
SARS-CoV-2
hamster
reinfection
transmission
vaccine
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
07 Nov 2023
07 Nov 2023
Historique:
medline:
2
11
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
ppublish
Résumé
The ongoing SARS-CoV-2 epidemic was marked by the repeated emergence and replacement of "variants" with genetic and phenotypic distance from the ancestral strains, the most recent examples being viruses of the Omicron lineage. Here, we describe a hamster direct contact exposure challenge model to assess protection against reinfection conferred by either vaccination or prior infection. We found that two doses of self-amplifying RNA vaccine based on the ancestral Spike ameliorated weight loss following Delta infection and decreased viral loads but had minimal effect on Omicron BA.1 infection. Prior vaccination followed by Delta or BA.1 breakthrough infections led to a high degree of cross-reactivity to all tested variants, suggesting that repeated exposure to antigenically distinct Spikes, via infection and/or vaccination drives a cross-reactive immune response. Prior infection with ancestral or Alpha variant was partially protective against BA.1 infection, whereas all animals previously infected with Delta and exposed to BA.1 became reinfected, although they shed less virus than BA.1-infected naive hamsters. Hamsters reinfected with BA.1 after prior Delta infection emitted infectious virus into the air, indicating that they could be responsible for onwards airborne transmission. We further tested whether prior infection with BA.1 protected from reinfection with Delta or later Omicron sublineages BA.2, BA.4, or BA.5. BA.1 was protective against BA.2 but not against Delta, BA.4, or BA.5 reinfection. These findings suggest that cohorts whose only immune experience of COVID-19 is Omicron BA.1 infection may be vulnerable to future circulation of reemerged Delta-like derivatives, as well as emerging Omicron sublineages.
Identifiants
pubmed: 37903249
doi: 10.1073/pnas.2308655120
pmc: PMC10636328
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2308655120Références
N Engl J Med. 2022 Oct 27;387(17):1620-1622
pubmed: 36198139
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
N Engl J Med. 2022 Feb 3;386(5):494-496
pubmed: 34965358
Lancet. 2022 Jan 15;399(10321):234-236
pubmed: 34942101
Nat Commun. 2020 Jul 9;11(1):3523
pubmed: 32647131
mBio. 2023 Apr 25;14(2):e0007823
pubmed: 37036339
Immunity. 2022 Sep 13;55(9):1725-1731.e4
pubmed: 35973428
Nat Commun. 2023 Jul 10;14(1):4078
pubmed: 37429851
EBioMedicine. 2023 Jul;93:104677
pubmed: 37352827
Virus Evol. 2022 Aug 11;8(2):veac050
pubmed: 35996593
Nature. 2022 Dec;612(7940):540-545
pubmed: 36323336
N Engl J Med. 2022 Mar 31;386(13):1288-1290
pubmed: 35139269
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
Clin Infect Dis. 2021 Oct 5;73(7):e1870-e1877
pubmed: 32634826
Vaccine. 2022 May 3;40(20):2848-2855
pubmed: 35396165
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Nat Commun. 2022 Aug 8;13(1):4610
pubmed: 35941149
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
Viruses. 2022 Mar 13;14(3):
pubmed: 35337002
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Commun Biol. 2023 Mar 18;6(1):288
pubmed: 36934204
Nat Med. 2022 Sep;28(9):1785-1790
pubmed: 35760080
Nat Microbiol. 2020 Oct;5(10):1299-1305
pubmed: 32651556
Cell Rep. 2022 Apr 19;39(3):110688
pubmed: 35421378
Science. 2023 Oct 6;382(6666):eadj0070
pubmed: 37797027
Sci Immunol. 2022 Sep 16;7(75):eabq2427
pubmed: 35653438
Nat Microbiol. 2022 Aug;7(8):1161-1179
pubmed: 35798890
PLoS Pathog. 2023 Apr 4;19(4):e1011293
pubmed: 37014911
Cell. 2022 Mar 3;185(5):872-880.e3
pubmed: 35123650
PLoS Pathog. 2020 Feb 25;16(2):e1008362
pubmed: 32097448
Nat Microbiol. 2021 Jul;6(7):899-909
pubmed: 33907312
Cell. 2022 Jun 9;185(12):2116-2131.e18
pubmed: 35662412
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Cell Rep. 2022 Feb 8;38(6):110344
pubmed: 35093235
N Engl J Med. 2021 Dec 30;385(27):2585-2586
pubmed: 34910864
Nature. 2022 Mar;603(7902):687-692
pubmed: 35062015
PLoS Biol. 2021 Feb 25;19(2):e3001091
pubmed: 33630831
Nat Commun. 2022 Sep 23;13(1):5573
pubmed: 36151099
Sci Immunol. 2022 Sep 23;7(75):eabq4450
pubmed: 35737747
J Virol. 2023 Jan 31;97(1):e0136622
pubmed: 36633406
Cell Rep. 2022 Mar 15;38(11):110515
pubmed: 35263638
Nat Commun. 2022 Dec 13;13(1):7701
pubmed: 36513653